AMGEN INC — Director's Dealing 2021

Nov 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2021-11-01

Reporting Person: Johnston Lori A (EVP, HR)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	F	1352	$206.97	Disposed	36269	Direct

Footnotes

F1: These shares include the following RSUs granted under the Company's equity plans: 690 RSUs which will vest on 4/27/2022; 1,361 RSUs which will vest in installments of 670 on 5/3/2022 and 691 on 5/3/2023; 5,226 RSUs which will vest in installments of 2,574 on 11/1/2022 and 2,652 on 11/1/2023; 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024; and 3,296 RSUs which vest in installments of 1,087 on 4/30/2023, 1,088 on 04/30/2024 and 1,121 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 668 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.